Iovance Biotherapeutics, Inc. (IOVA)
This Is the Biggest Risk With Iovance Biotherapeutics Stock
Iovance Biotherapeutics obtained accelerated approval for its cell therapy, Amtagvi, earlier this year. The company has begun rolling it out, and it presents a big opportunity for the business.
Up 47% in 2024: Where Will Iovance Biotherapeutics Be in 5 Years?
The Food and Drug Administration approved Iovance Biotherapeutics' first therapy, Amtagvi, in February. Amtagvi is a complicated treatment made from immune cells found in tumor biopsies.
This 1 Big Risk Is Also 1 Big Opportunity for Iovance Biotherapeutics Stock
Iovance Biotherapeutics is now selling its first cell therapy, Amtagvi. Amtagvi requires significant logistical and manufacturing coordination.
Iovance's Tumor-Fighting TILs Are Just Warming Up (Rating Upgrade)
Iovance's Q2 2024 revenue of $31.1 million surpassed analyst expectations. Amtagvi, Iovance's TIL therapy, generated $12.8 million in its first full quarter post-approval. Iovance's ongoing trials in NSCLC and endometrial cancer could expand lifileucel's market potential.
Why Iovance Biotherapeutics Shares Are Soaring Today
Although only approved in February, Iovance's Amtagvi is already selling well. The drug in question also has potential as a treatment for several other types of cancer.
Why Is Iovance Bio (IOVA) Stock Up 18% Today?
Iovance Biotherapeutics (NASDAQ: IOVA ) stock is taking a beating on Friday after the biotechnology company announced its earnings for the second quarter of the year. Iovance Biotherapeutics starts that report with adjusted earnings per share of -34 cents.
Skin Cancer-Focused Iovance Biotherapeutics Reports Better-Than-Expected 2024, 2025 Outlook, Stock Surges
Iovance Biotherapeutics Inc IOVA stock is trading higher on Friday after the company issued upbeat guidance for 2024 and 2025 and better-than-expected second-quarter earnings.
Iovance (IOVA) Q2 Earnings Beat, Stock Up on Upbeat Sales View
Iovance (IOVA) reports better-than-expected second-quarter results. Shares price rises on the back of encouraging product revenue guidance issued by management for 2024 and 2025.
Iovance Biotherapeutics, Inc. (IOVA) Q2 2024 Earnings Call Transcript
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Sara Pellegrino – Senior Vice President, Investor Relations and Corporate Communications Fred Vogt – Interim President and Chief Executive Officer Jim Ziegler – Executive Vice President-Commercial Igor Bilinsky – Chief Operating Officer Jean-Marc Bellemin – Chief Financial Officer Friedrich Finckenstein – Chief Medical Officer Brian Gastman – Executive Vice President-Medical Affairs Conference Call Participants Michael Yee – Jefferies Peter Lawson – Barclays Andrea Tan – Goldman Sachs Yanan Zhu – Wells Fargo Securities Tyler Van Buren – TD Cowen Ben Burnett – Stifel Colleen Kusy – Baird Asthika Goonewardene – Truist Reni Benjamin – Citizens JMP Operator Welcome to the Iovance Biotherapeutics Conference Call to discuss Second Quarter 2024 Results and Recent Corporate Updates. My name is Daniel and I will be your operator for today's call.
Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Tops Revenue Estimates
Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.47 per share a year ago.
Iovance Biotherapeutics (IOVA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Iovance Biotherapeutics (IOVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Iovance Biotherapeutics Attracted a Downgrade. Is It Time to Sell?
An analyst from Piper Sandler recently downgraded Iovance Biotherapeutics and lowered the firm's price target on the stock The FDA approved Iovance's first drug in February, and investors still aren't sure if its commercial launch can succeed. An ongoing clinical trial could greatly expand the addressable patient population for the company's lead drug.
